MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

NCT06712875 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Low Grade Glioma
High Grade Glioma

Interventions

DRUG: Trametinib and Nivolumab
DRUG: Dabrafenib, trametinib, nivolumab

Sponsor

Ann & Robert H Lurie Children's Hospital of Chicago